## Alessandro Sticchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/679804/publications.pdf

Version: 2024-02-01

62 papers

1,149 citations

393982 19 h-index 32 g-index

73 all docs

73 docs citations

73 times ranked 1853 citing authors

#	Article	IF	CITATIONS
1	Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index. Heart and Vessels, 2022, 37, 1471-1477.	0.5	1
2	latrogenic aorta oronary dissection: Case report and systematic review. Catheterization and Cardiovascular Interventions, 2021, 97, E900-E910.	0.7	8
3	Computed tomography analysis of coronary ostia location following valveâ€nâ€valve transcatheter aortic valve replacement with the ACURATE neo valve: Implications for coronary access. Catheterization and Cardiovascular Interventions, 2021, 98, 595-604.	0.7	6
4	Patient selection, procedural planning and interventional guidance for transcatheter aortic valve intervention. Minerva Cardiology and Angiology, 2021, 69, 671-683.	0.4	13
5	Reply. JACC: Cardiovascular Interventions, 2021, 14, 585-586.	1.1	O
6	Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. JACC: Cardiovascular Interventions, 2021, 14, 873-878.	1.1	4
7	Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2021, 14, 1085-1092.	1.1	2
8	Diabetes and mortality in patients with COVID-19: Are we missing the link?., 2021, 25, 376-379.		6
9	Adoption of a new automated optical coherence tomography software to obtain a lipid plaque spread-out plot. International Journal of Cardiovascular Imaging, 2021, 37, 3129-3135.	0.7	3
10	Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19. Atherosclerosis, 2021, 328, 136-143.	0.4	25
11	Usefulness of Adding Pre-procedural Glycemia to the Mehran Score to Enhance Its Ability to Predict Contrast-induced Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention Development and Validation of a Predictive Model. American Journal of Cardiology, 2021, 155, 16-22.	0.7	10
12	Learning From Failure at the CUTTING-EDGE of Transcatheter Mitral Valve Therapies. JACC: Cardiovascular Interventions, 2021, 14, 2022-2026.	1.1	0
13	Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients. Journal of Cardiovascular Computed Tomography, 2021, 15, 421-430.	0.7	22
14	Retrograde Retrieval of a Novel Large Mitral Clip After Embolization Into the Left Ventricle. JACC: Case Reports, 2021, 3, 1561-1568.	0.3	4
15	Outcomes After Transcatheter Aortic Valve Replacement in Bicuspid Versus Tricuspid Anatomy. JACC: Cardiovascular Interventions, 2021, 14, 2144-2155.	1.1	37
16	730 Prediction of type 4a myocardial infarction with the angiography-derived haemodynamic (added) index. European Heart Journal Supplements, 2021, 23, .	0.0	0
17	Contributors to survival benefit of dual versus single antithrombotic therapy in chronic coronary syndrome. European Journal of Internal Medicine, 2020, 72, 97-98.	1.0	1
18	Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. American Journal of Cardiology, 2020, 134, 83-90.	0.7	18

#	Article	lF	CITATIONS
19	Acute Tricuspid Valve Remodelling After MitraClip Deployment: Rationale for a Dual-Staged Procedure. Canadian Journal of Cardiology, 2020, 36, 1831.e1-1831.e3.	0.8	2
20	Functional and Echocardiographic Improvement After Transcatheter Repair for TricuspidÂRegurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2719-2729.	1.1	29
21	Subclinical atrial fibrillation: when to give NAO?. European Heart Journal Supplements, 2020, 22, E105-E109.	0.0	1
22	Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. Cardiovascular Intervention and Therapeutics, 2020, 35, 117-129.	1.2	30
23	Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2088-2101.	1.2	57
24	Meta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy after Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy Treatment. American Journal of Cardiology, 2019, 124, 627-635.	0.7	16
25	The coâ€predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. Diabetes/Metabolism Research and Reviews, 2019, 35, e3145.	1.7	5
26	Transradial versus transfemoral ancillary approach in complex structural, coronary, and peripheral interventions. Results from the multicenter ancillary registry: A study of the Italian Radial Club. Catheterization and Cardiovascular Interventions, 2018, 91, 97-102.	0.7	15
27	Fractional flow reserve (FFR) as a guide to treat coronary artery disease. Expert Review of Cardiovascular Therapy, 2018, 16, 465-477.	0.6	16
28	Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound. Catheterization and Cardiovascular Interventions, 2017, 89, 789-797.	0.7	5
29	Thrombus aspiration in primary percutaneous coronary intervention: still a valid option with improved technique in selected patients!. Cardiovascular Diagnosis and Therapy, 2017, 7, S110-S114.	0.7	5
30	Transâ€subclavian versus transapical access for transcatheter aortic valve implantation: A multicenter study. Catheterization and Cardiovascular Interventions, 2016, 87, 332-338.	0.7	46
31	Treatment of drugâ€eluting stent restenosis: Comparison between drugâ€eluting balloon versus secondâ€generation drugâ€eluting stents from a retrospective observational study. Catheterization and Cardiovascular Interventions, 2016, 88, 522-528.	0.7	15
32	Clinical outcomes following bioresorbable scaffold implantation in small vessels. International Journal of Cardiology, 2016, 207, 59-61.	0.8	2
33	Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure. Catheterization and Cardiovascular Interventions, 2016, 87, 832-836.	0.7	6
34	Biolimus-Eluting StenT For de-novo coRonary artery dlsease in patiENts with Diabetes mellituS. Journal of Cardiovascular Medicine, 2016, 17, 729-735.	0.6	1
35	Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1135-1143.	0.4	8
36	Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). American Journal of Cardiology, 2016, 117, 813-819.	0.7	16

#	Article	IF	Citations
37	Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds. EuroIntervention, 2016, 11, 1355-1362.	1.4	23
38	A Comparison Between First-Generation and Second-Generation Transcatheter Aortic Valve Implantation (TAVI) Devices: A Propensity-Matched Single-Center Experience. Journal of Invasive Cardiology, 2016, 28, 210-6.	0.4	19
39	TCT-430 Ancillary radial versus femoral/brachial approach to reduce vascular complications in complex coronary, peripheral and structural interventions. Preliminary results of a study from the Italian Radial Club. Journal of the American College of Cardiology, 2015, 66, B175-B176.	1.2	2
40	First generation versus new generation drugâ€eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2015, 85, E63-9.	0.7	8
41	Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheterization and Cardiovascular Interventions, 2015, 85, E10-E15.	0.7	53
42	Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategy. Catheterization and Cardiovascular Interventions, 2015, 86, 644-652.	0.7	25
43	Impact of Strut Width in Periprocedural Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 900-909.	1.1	44
44	Surgical treatment of paravalvular leak: Long-term results in a single-center experience (up to 14) Tj ETQq0 0 0	rgBT.¦Qver	ock 10 Tf 50
45	TCT-521 Clinical outcomes after bioresorbable scaffold implantation in patients with a high prevalence of complex lesions: the Milan experience. Journal of the American College of Cardiology, 2015, 66, B213.	1.2	1
46	Causes and timing of death during long-term follow-up after transcatheter aortic valve replacement. American Heart Journal, 2014, 168, 798-806.	1.2	36
47	Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience. European Heart Journal Cardiovascular Imaging, 2014, 15, 1161-1167.	0.5	62
48	Extended followâ€up following "fullâ€metal jacketâ€percutaneous coronary interventions with drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2014, 84, 1042-1050.	0.7	21
49	Comparison of abluminal biodegradable polymer biolimusâ€eluting stents and durable polymer everolimusâ€eluting stents in the treatment of coronary bifurcations. Catheterization and Cardiovascular Interventions, 2014, 83, 889-895.	0.7	8
50	Short-term outcomes following "full-plastic jacket―everolimus-eluting bioresorbable scaffold implantation. International Journal of Cardiology, 2014, 177, 607-609.	0.8	9
51	TCT-609 Comparison of one year outcomes in real world patients treated with a polymer free amphilimus eluting coronary stent versus second generation everolimus eluting stents. Journal of the American College of Cardiology, 2014, 64, B178.	1.2	0
52	Drugâ€Eluting Balloon in the Treatment of Inâ€Stent Restenosis and Diffuse Coronary Artery Disease: Realâ€World Experience from Our Registry. Journal of Interventional Cardiology, 2014, 27, 348-355.	0.5	20
53	Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Severely Stenotic Bicuspid Versus Tricuspid or Nonbicuspid Valves. American Journal of Cardiology, 2014, 113, 1390-1393.	0.7	79
54	The Role of Drug-Eluting Balloons Alone or in Combination With Drug-Eluting Stents in the Treatment of De Novo Diffuse Coronary Disease. JACC: Cardiovascular Interventions, 2013, 6, 1153-1159.	1.1	41

#	Article	IF	CITATIONS
55	Renal denervation in a patient with two renal accessory arteries: A case report. Blood Pressure, 2013, 22, 325-328.	0.7	1
56	First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations. Cardiovascular Revascularization Medicine, 2013, 14, 311-315.	0.3	21
57	TCT-465 Drug-Eluting Balloon in the Treatment of Instent Restenosis and Diffuse Coronary Artery Disease; Real World Experience from a Single Center Registry. Journal of the American College of Cardiology, 2013, 62, B142.	1.2	O
58	Comparison of First- and Second-Generation Drug-Eluting Stents in Saphenous Vein Grafts Used as Aorto-Coronary Conduits. American Journal of Cardiology, 2013, 112, 318-322.	0.7	20
59	Newly available and recent advances in drug-eluting stents. Expert Review of Cardiovascular Therapy, 2013, 11, 555-566.	0.6	4
60	Comparison of Incidence and Predictors of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Using the CoreValve Versus the Edwards Valve. American Journal of Cardiology, 2013, 112, 554-559.	0.7	118
61	Everolimus-eluting and biolimus-eluting stents for the treatment of coronary bifurcations. European Heart Journal, 2013, 34, P3074-P3074.	1.0	0
62	A comparison of first- and second-generation drug-eluting stents in saphenous vein grafts. European Heart Journal, 2013, 34, P1210-P1210.	1.0	0